Brief: Inhibikase Therapeutics Receives FDA Orphan Drug Designation For The Treatment Of Multiple System Atrophy
04/10/2023 13:47
Oct 4 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS RECEIVES FDA ORPHAN DRUG
DESIGNATION FOR
RISVODETINIB FOR THE TREATMENT OF MULTIPLE SYSTEM ATROPHY
Source text for Eikon: ID:nGNX2JGZvP
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share